Literature DB >> 29438690

c-Raf in KRas Mutant Cancers: A Moving Target.

Frank McCormick1.   

Abstract

Therapies for KRas cancers remain a major clinical need. In the current issue of Cancer Cell, Sanclemente and coworkers in Mariano Barbacid's group validate c-Raf as a prime target for these cancers. c-Raf ablation caused regression of advanced KRasG12V/Trp53 tumors, without obvious systemic toxicity and without affecting MAPK signaling.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29438690      PMCID： PMC6464632          DOI： 10.1016/j.ccell.2018.01.017

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  8 in total

1.  A CRAF/glutathione-S-transferase P1 complex sustains autocrine growth of cancers with KRAS and BRAF mutations.

Authors:  Yoshiro Niitsu; Yasushi Sato; Kunihiro Takanashi; Tsuyoshi Hayashi; Naoko Kubo-Birukawa; Fumiko Shimizu; Naoki Fujitani; Rai Shimoyama; Takehiro Kukitsu; Wataru Kurata; Yasuyuki Tashiro; Irving Listowsky
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-27       Impact factor: 11.205

2.  Implications of the HDAC6-ERK1 feed-forward loop in immunotherapy.

Authors:  Jheng-Yu Wu; Niko Moses; Wenlong Bai; Xiaohong Mary Zhang
Journal:  J Immunol Sci       Date:  2018-06-13

Review 3.  Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation.

Authors:  Thomas Yul Avery; Natalie Köhler; Robert Zeiser; Tilman Brummer; Dietrich Alexander Ruess
Journal:  Front Oncol       Date:  2022-07-27       Impact factor: 5.738

4.  Peptidomimetics designed to bind to RAS effector domain are promising cancer therapeutic compounds.

Authors:  Chiara Pallara; Debora Cabot; Josep Rivas; Sonia Brun; Jesús Seco; Baraa Abuasaker; Teresa Tarragó; Montserrat Jaumot; Roger Prades; Neus Agell
Journal:  Sci Rep       Date:  2022-09-22       Impact factor: 4.996

Review 5.  Emerging strategies to target RAS signaling in human cancer therapy.

Authors:  Kun Chen; Yalei Zhang; Ling Qian; Peng Wang
Journal:  J Hematol Oncol       Date:  2021-07-23       Impact factor: 17.388

6.  Non-canonical Raf-1/p70S6K signalling in non-small-cell lung cancer.

Authors:  Zhixin Qiu; Bingwei Ye; Shuang Zhao; Xin Li; Lei Li; Ximing Mo; Weimin Li
Journal:  J Cell Mol Med       Date:  2019-09-21       Impact factor: 5.310

Review 7.  Recent Developments in Targeting RAS Downstream Effectors for RAS-Driven Cancer Therapy.

Authors:  Ozge Tatli; Gizem Dinler Doganay
Journal:  Molecules       Date:  2021-12-14       Impact factor: 4.411

8.  DFMO Improves Survival and Increases Immune Cell Infiltration in Association with MYC Downregulation in the Pancreatic Tumor Microenvironment.

Authors:  Sai Preethi Nakkina; Sarah B Gitto; Jordan M Beardsley; Veethika Pandey; Michael W Rohr; Jignesh G Parikh; Otto Phanstiel; Deborah A Altomare
Journal:  Int J Mol Sci       Date:  2021-12-07       Impact factor: 6.208
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.